83 FR 2300 - Qualification of Drivers; Exemption Applications; Diabetes Mellitus
DEPARTMENT OF TRANSPORTATION
Federal Motor Carrier Safety Administration Federal Register Volume 83, Issue 10 (January 16, 2018)
Federal Motor Carrier Safety Administration
Federal Register Volume 83, Issue 10 (January 16, 2018)
| Page Range | 2300-2306 | |
| FR Document | 2018-00562 |
[Federal Register Volume 83, Number 10 (Tuesday, January 16, 2018)] [Notices] [Pages 2300-2306] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-00562] ----------------------------------------------------------------------- DEPARTMENT OF TRANSPORTATION Federal Motor Carrier Safety Administration [Docket No. FMCSA-2017-0287] Qualification of Drivers; Exemption Applications; Diabetes Mellitus AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT. ACTION: Notice of applications for exemption; request for comments. ----------------------------------------------------------------------- SUMMARY: FMCSA announces receipt of applications from 39 individuals for an exemption from the prohibition in the Federal Motor Carrier Safety Regulations (FMCSRs) against persons with insulin-treated diabetes mellitus (ITDM) operating a commercial motor vehicle (CMV) in interstate commerce. If granted, the exemptions would enable these individuals with ITDM to operate CMVs in interstate commerce. DATES: Comments must be received on or before February 15, 2018. ADDRESSES: You may submit comments bearing the Federal Docket Management System (FDMS) Docket No. FMCSA-2017-0287 using any of the following methods:Federal eRulemaking Portal: Go to http://www.regulations.gov. Follow the online instructions for submitting comments. Mail: Docket Management Facility; U.S. Department of Transportation, 1200 New Jersey Avenue SE, West Building Ground Floor, Room W12-140, Washington, DC 20590-0001. Hand Delivery: West Building Ground Floor, Room W12-140, 1200 New Jersey Avenue SE, Washington, DC, between 9 a.m. and 5 p.m., e.t., Monday through Friday, except Federal Holidays. Fax: 1-202-493-2251. Instructions: Each submission must include the Agency name and the docket number(s) for this notice. Note that all comments received will be posted without change to http://www.regulations.gov, including any personal information provided. Please see the Privacy Act heading below for further information. Docket: For access to the docket to read background documents or comments, go to http://www.regulations.gov at any time or Room W12-140 on the ground level of the West Building, 1200 New Jersey Avenue SE, Washington, DC, between 9 a.m. and 5 p.m., e.t., Monday through Friday, except Federal holidays. The FDMS is available 24 hours each day e.t., 365 days each year. If you want acknowledgment that we received your comments, please include a self-addressed, stamped envelope or postcard or print the acknowledgement page that appears after submitting comments online. Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits comments from the public to better inform its rulemaking process. DOT posts these comments, without edit, including any personal information the commenter provides, to http://www.regulations.gov, as described in the system of records notice (DOT/ALL-14 FDMS), which can be reviewed at http://www.dot.gov/privacy. FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief, Medical Programs Division, (202) 366-4001, [email protected], FMCSA, Department of Transportation, 1200 New Jersey Avenue SE, Room W64-224, Washington, DC 20590-0001. Office hours are 8:30 a.m. to 5 p.m., e.t., Monday through Friday, except Federal holidays. If you have questions regarding viewing or submitting material to the docket, contact Docket Services, telephone (202) 366-9826. SUPPLEMENTARY INFORMATION: I. Background Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption from the FMCSRs for a five-year period if it finds ``such exemption would likely achieve a level of safety that is equivalent to or greater than the level that would be achieved absent such exemption.'' The statute also allows the Agency to renew exemptions at the end of the five-year period. FMCSA grants exemptions from the FMCSRs for a two- year period to align with the maximum duration of a driver's medical certification. The 39 individuals listed in this notice have requested an exemption from the diabetes prohibition in 49 CFR 391.41(b)(3). Accordingly, the Agency will evaluate the qualifications of each applicant to determine whether granting the exemption will achieve the required level of safety mandated by statute. The physical qualification standard for drivers regarding diabetes found in [[Page 2301]] 49 CFR 391.41(b)(3) states that a person is physically qualified to drive a CMV if that person has no established medical history or clinical diagnosis of diabetes mellitus currently requiring insulin for control. The Agency established the current requirement for diabetes in 1970 because several risk studies indicated that drivers with diabetes had a higher rate of crash involvement than the general population. FMCSA established its diabetes exemption program, based on the Agency's July 2000 study entitled ``A Report to Congress on the Feasibility of a Program to Qualify Individuals with Insulin-Treated Diabetes Mellitus to Operate in Interstate Commerce as Directed by the Transportation Act for the 21st Century.'' The report concluded that a safe and practicable protocol to allow some drivers with ITDM to operate CMVs is feasible. The September 3, 2003 (68 FR 52441), Federal Register notice in conjunction with the November 8, 2005 (70 FR 67777), Federal Register notice provides the current protocol for allowing such drivers to operate CMVs in interstate commerce. FMCSA notes that section 4129 of the Safe, Accountable, Flexible and Efficient Transportation Equity Act: A Legacy for Users requires the Secretary to revise its diabetes exemption program established on September 3, 2003 (68 FR 52441). The revision must provide for individual assessment of drivers with diabetes mellitus, and be consistent with the criteria described in section 4018 of the Transportation Equity Act for the 21st Century (49 U.S.C. 31305). Section 4129 requires: (1) Elimination of the requirement for three years of experience operating CMVs while being treated with insulin; and (2) establishment of a specified minimum period of insulin use to demonstrate stable control of diabetes before being allowed to operate a CMV. In response to section 4129, FMCSA made immediate revisions to the diabetes exemption program established by the September 3, 2003 notice. FMCSA discontinued use of the three-year driving experience and fulfilled the requirements of section 4129 while continuing to ensure that operation of CMVs by drivers with ITDM will achieve the requisite level of safety required of all exemptions granted under 49 U.S.C. 31136 (e). Section 4129(d) also directed FMCSA to ensure that drivers of CMVs with ITDM are not held to a higher standard than other drivers, with the exception of limited operating, monitoring and medical requirements that are deemed medically necessary. The FMCSA concluded that all of the operating, monitoring and medical requirements set out in the September 3, 2003, notice, except as modified, were in compliance with section 4129(d). Therefore, all of the requirements set out in the September 3, 2003, notice, except as modified by the notice in the Federal Register on November 8, 2005 (70 FR 67777), remain in effect. II. Qualifications of Applicants Rodney C. Adams Mr. Adams, 55, has had ITDM since 2014. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Adams understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Adams meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds an operator's license from Connecticut. Craig A. Ballard Mr. Ballard, 52, has had ITDM since 2017. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Ballard understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Ballard meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from Georgia. David E. Bauman Mr. Bauman, 61, has had ITDM since 2016. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Bauman understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Bauman meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from Nebraska. Ryan C. Bayless Mr. Bayless, 22, has had ITDM since 2005. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Bayless understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Bayless meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he has stable nonproliferative diabetic retinopathy. He holds an operator's license from Missouri. Dennis E. Bellerive Mr. Bellerive, 68, has had ITDM since 2017. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Bellerive understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Bellerive meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class B CDL from New Hampshire. Billy G. Boren, Jr. Mr. Boren, 43, has had ITDM since 2017. His endocrinologist examined him in 2017 and certified that he has had no [[Page 2302]] severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Boren understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Boren meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class D CDL from Kentucky. Joseph H. Bove Mr. Bove, 50, has had ITDM since 2015. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Bove understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Bove meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds an operator's license from New York. Gary W. Brooks Mr. Brooks, 61, has had ITDM since 2001. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Brooks understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Brooks meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he has stable nonproliferative diabetic retinopathy. He holds an operator's license from California. Carl E. Bryant Mr. Bryant, 72, has had ITDM since 2015. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Bryant understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Bryant meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class B CDL from New York. Vernon C. Buchanan Mr. Buchanan, 58, has had ITDM since 2016. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Buchanan understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Buchanan meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from Pennsylvania. Phillip L. Butler Mr. Butler, 36, has had ITDM since 2013. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Butler understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Butler meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from Virginia. Tyler H. Cardwell Mr. Cardwell, 34, has had ITDM since 2006. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Cardwell understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Cardwell meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds an operator's license from Mississippi. Arleigh D. Chapman Mr. Chapman, 65, has had ITDM since 2013. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Chapman understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Chapman meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from Pennsylvania. Richard J. Dinzeo Mr. Dinzeo, 48, has had ITDM since 2010. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Dinzeo understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Dinzeo meets the requirements of the vision standard at [[Page 2303]] 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class B CDL from Minnesota. Mark A. Donahoo Mr. Donahoo, 52, has had ITDM since 2017. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Donahoo understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Donahoo meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from Missouri. James W. Felske Mr. Felske, 49, has had ITDM since 1989. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Felske understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Felske meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds an operator's license from Illinois. Christopher L. Fleming Mr. Fleming, 45, has had ITDM since 2016. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Fleming understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Fleming meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds an operator's license from Georgia. Jason R. Gassaway Mr. Gassaway, 43, has had ITDM since 2017. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Gassaway understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Gassaway meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from New Mexico. Owen D. Gibbons Mr. Gibbons, 41, has had ITDM since 2015. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Gibbons understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Gibbons meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from Pennsylvania. James L. Goodwin, 3rd Mr. Goodwin, 38, has had ITDM since 2009. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Goodwin understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Goodwin meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds an operator's license from Maryland. Richard J. Grenvik Mr. Grenvik, 60, has had ITDM since 2017. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Grenvik understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Grenvik meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from Minnesota. Michael K. Gunn Mr. Gunn, 64, has had ITDM since 2004. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Gunn understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Gunn meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class B CDL from Wisconsin. Kermit F. Hicks, Jr. Mr. Hicks, 49, has had ITDM since 2006. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or [[Page 2304]] more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Hicks understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Hicks meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds an operator's license from Ohio. Raymond D. Hill Mr. Hill, 67, has had ITDM since 2015. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Hill understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Hill meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from Minnesota. Rob D. Karaus Mr. Karaus, 41, has had ITDM since 1994. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Karaus understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Karaus meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he has stable nonproliferative diabetic retinopathy. He holds an operator's license from Indiana. Garnie T. Mauk, Jr. Mr. Mauk, 58, has had ITDM since 2017. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Mauk understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Mauk meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he has stable nonproliferative diabetic retinopathy. He holds a Class A CDL from Tennessee. Jose Medelez Mr. Medelez, 59, has had ITDM since 2017. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Medelez understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Medelez meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he has stable nonproliferative diabetic retinopathy. He holds a Class A CDL from Oregon. Alexander P. Paice Mr. Paice, 37, has had ITDM since 2013. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Paice understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Paice meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds an operator's license from Utah. Charles Petit-Homme Mr. Petit-Homme, 59, has had ITDM since 2015. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Petit-Homme understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Petit-Homme meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class B CDL from New York. Phillip G. Putzke Mr. Putzke, 37, has had ITDM since 1988. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Putzke understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Putzke meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he has stable nonproliferative diabetic retinopathy. He holds an operator's license from South Dakota. James A. Smit Mr. Smit, 52, has had ITDM since 2015. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Smit understands diabetes management and monitoring and has stable control of his diabetes using insulin. Mr. Smit meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from Minnesota. [[Page 2305]] Gregory E. Sorenson Mr. Sorenson, 54, has had ITDM since 2016. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Sorenson understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Sorenson meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds an operator's license from Indiana. Sharon P. Soucy Ms. Soucy, 68, has had ITDM since 2017. Her endocrinologist examined her in 2017 and certified that she has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. Her endocrinologist certifies that Ms. Soucy understands diabetes management and monitoring has stable control of her diabetes using insulin, and is able to drive a CMV safely. Ms. Soucy meets the requirements of the vision standard at 49 CFR 391.41(b)(10). Her ophthalmologist examined her in 2017 and certified that she does not have diabetic retinopathy. She holds a Class B CDL from Alaska. Robin T. Spence Ms. Spence, 61, has had ITDM since 2015. Her endocrinologist examined her in 2017 and certified that she has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. Her endocrinologist certifies that Ms. Spence understands diabetes management and monitoring has stable control of her diabetes using insulin, and is able to drive a CMV safely. Ms. Spence meets the requirements of the vision standard at 49 CFR 391.41(b)(10). Her optometrist examined her in 2017 and certified that she does not have diabetic retinopathy. She holds a Class A CDL from Oklahoma. Anthony P. Sweeney Mr. Sweeney, 52, has had ITDM since 2015. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Sweeney understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Sweeney meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he has stable nonproliferative diabetic retinopathy. He holds a Class A CDL from Maryland. Richard A. Sweeting Mr. Sweeting, 50, has had ITDM since 2017. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Sweeting understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Sweeting meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class A CDL from Georgia. Steven J. Voorhees Mr. Voorhees, 62, has had ITDM since 2012. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Voorhees understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Voorhees meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds an operator's license from Montana. Jeffery E. Wall Mr. Wall, 46, has had ITDM since 2016. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Wall understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Wall meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His ophthalmologist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds an operator's license from North Carolina. Samuel E. Ward Mr. Ward, 67, has had ITDM since 2010. His endocrinologist examined him in 2017 and certified that he has had no severe hypoglycemic reactions resulting in loss of consciousness, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning in the past 12 months and no recurrent (two or more) severe hypoglycemic episodes in the last five years. His endocrinologist certifies that Mr. Ward understands diabetes management and monitoring, has stable control of his diabetes using insulin, and is able to drive a CMV safely. Mr. Ward meets the requirements of the vision standard at 49 CFR 391.41(b)(10). His optometrist examined him in 2017 and certified that he does not have diabetic retinopathy. He holds a Class B CDL from Kansas. III. Request for Comments In accordance with 49 U.S.C. 31136(e) and 31315, FMCSA requests public comment from all interested persons on the exemption petitions described in this notice. We will consider all comments received before the close of business on the closing date indicated in the dates section of the notice. IV. Submitting Comments You may submit your comments and material online or by fax, mail, or hand delivery, but please use only one of these means. FMCSA recommends that you include your name and a mailing [[Page 2306]] address, an email address, or a phone number in the body of your document so that FMCSA can contact you if there are questions regarding your submission. To submit your comment online, go to http://www.regulations.gov and in the search box insert the docket number FMCSA-2017-0287 and click the search button. When the new screen appears, click on the blue ``Comment Now!'' button on the right hand side of the page. On the new page, enter information required including the specific section of this document to which each comment applies, and provide a reason for each suggestion or recommendation. If you submit your comments by mail or hand delivery, submit them in an unbound format, no larger than 8\1/2\ by 11 inches, suitable for copying and electronic filing. If you submit comments by mail and would like to know that they reached the facility, please enclose a stamped, self-addressed postcard or envelope. We will consider all comments and materials received during the comment period. FMCSA may issue a final determination at any time after the close of the comment period. V. Viewing Comments and Documents To view comments, as well as any documents mentioned in this preamble, go to http://www.regulations.gov and in the search box insert the docket number FMCSA-2017-0287 and click ``Search.'' Next, click ``Open Docket Folder'' and you will find all documents and comments related to this notice. Issued on: January 5, 2018. Larry W. Minor, Associate Administrator for Policy. [FR Doc. 2018-00562 Filed 1-12-18; 8:45 am] BILLING CODE 4910-EX-P
![2300 Federal Register / Vol. 83, No. 10 / Tuesday, January 16, 2018 / Notices
free since 2001. He takes anti-seizure FMCSA–2017–0253 and click ‘‘Search.’’ Docket: For access to the docket to
medication, with the dosage and Next, click ‘‘Open Docket Folder’’ and read background documents or
frequency remaining the same since you will find all documents and comments, go to http://
2001. His physician states that he is comments related to this notice. www.regulations.gov at any time or
supportive of Mr. Mills receiving an Issued on: January 5, 2018. Room W12–140 on the ground level of
exemption. Larry W. Minor,
the West Building, 1200 New Jersey
Avenue SE, Washington, DC, between 9
Jaime D. Paggen. Associate Administrator for Policy.
a.m. and 5 p.m., e.t., Monday through
Ms. Paggen, 40, has a history of [FR Doc. 2018–00603 Filed 1–12–18; 8:45 am]
Friday, except Federal holidays. The
epilepsy and has been seizure free since BILLING CODE 4910–EX–P FDMS is available 24 hours each day
2008. She takes anti-seizure medication, e.t., 365 days each year. If you want
with the dosage and frequency acknowledgment that we received your
remaining the same since 2008. Her DEPARTMENT OF TRANSPORTATION
comments, please include a self-
physician states that she is supportive of addressed, stamped envelope or
Federal Motor Carrier Safety
Ms. Paggen receiving an exemption. postcard or print the acknowledgement
Administration
III. Request for Comments page that appears after submitting
[Docket No. FMCSA–2017–0287] comments online.
In accordance with 49 U.S.C. 31136(e) Privacy Act: In accordance with 5
and 31315, FMCSA requests public Qualification of Drivers; Exemption U.S.C. 553(c), DOT solicits comments
comment from all interested persons on Applications; Diabetes Mellitus from the public to better inform its
the exemption petitions described in rulemaking process. DOT posts these
AGENCY: Federal Motor Carrier Safety
this notice. We will consider all comments, without edit, including any
Administration (FMCSA), DOT.
comments received before the close of personal information the commenter
business on the closing date indicated ACTION: Notice of applications for
exemption; request for comments. provides, to http://www.regulations.gov,
in the dates section of the notice. as described in the system of records
IV. Submitting Comments SUMMARY: FMCSA announces receipt of notice (DOT/ALL–14 FDMS), which can
applications from 39 individuals for an be reviewed at http://www.dot.gov/
You may submit your comments and
exemption from the prohibition in the privacy.
material online or by fax, mail, or hand
Federal Motor Carrier Safety FOR FURTHER INFORMATION CONTACT: Ms.
delivery, but please use only one of
Regulations (FMCSRs) against persons Christine A. Hydock, Chief, Medical
these means. FMCSA recommends that
with insulin-treated diabetes mellitus Programs Division, (202) 366–4001,
you include your name and a mailing
(ITDM) operating a commercial motor fmcsamedical@dot.gov, FMCSA,
address, an email address, or a phone
vehicle (CMV) in interstate commerce. If Department of Transportation, 1200
number in the body of your document
granted, the exemptions would enable New Jersey Avenue SE, Room W64–224,
so that FMCSA can contact you if there
these individuals with ITDM to operate Washington, DC 20590–0001. Office
are questions regarding your
CMVs in interstate commerce. hours are 8:30 a.m. to 5 p.m., e.t.,
submission.
To submit your comment online, go to DATES: Comments must be received on Monday through Friday, except Federal
http://www.regulations.gov and in the or before February 15, 2018. holidays. If you have questions
search box insert the docket number ADDRESSES: You may submit comments regarding viewing or submitting
FMCSA–2017–0253 and click the search bearing the Federal Docket Management material to the docket, contact Docket
button. When the new screen appears, System (FDMS) Docket No. FMCSA– Services, telephone (202) 366–9826.
click on the blue ‘‘Comment Now!’’ 2017–0287 using any of the following SUPPLEMENTARY INFORMATION:
button on the right hand side of the methods:
• Federal eRulemaking Portal: Go to I. Background
page. On the new page, enter
information required including the http://www.regulations.gov. Follow the Under 49 U.S.C. 31136(e) and 31315,
specific section of this document to online instructions for submitting FMCSA may grant an exemption from
which each comment applies, and comments. the FMCSRs for a five-year period if it
provide a reason for each suggestion or • Mail: Docket Management Facility; finds ‘‘such exemption would likely
recommendation. If you submit your U.S. Department of Transportation, 1200 achieve a level of safety that is
comments by mail or hand delivery, New Jersey Avenue SE, West Building equivalent to or greater than the level
submit them in an unbound format, no Ground Floor, Room W12–140, that would be achieved absent such
larger than 81⁄2 by 11 inches, suitable for Washington, DC 20590–0001. exemption.’’ The statute also allows the
copying and electronic filing. If you • Hand Delivery: West Building Agency to renew exemptions at the end
submit comments by mail and would Ground Floor, Room W12–140, 1200 of the five-year period. FMCSA grants
like to know that they reached the New Jersey Avenue SE, Washington, exemptions from the FMCSRs for a two-
facility, please enclose a stamped, self- DC, between 9 a.m. and 5 p.m., e.t., year period to align with the maximum
addressed postcard or envelope. Monday through Friday, except Federal duration of a driver’s medical
We will consider all comments and Holidays. certification.
materials received during the comment • Fax: 1–202–493–2251. The 39 individuals listed in this
period. FMCSA may issue a final Instructions: Each submission must notice have requested an exemption
determination at any time after the close include the Agency name and the from the diabetes prohibition in 49 CFR
daltland on DSKBBV9HB2PROD with NOTICES
of the comment period. docket number(s) for this notice. Note 391.41(b)(3). Accordingly, the Agency
that all comments received will be will evaluate the qualifications of each
V. Viewing Comments and Documents posted without change to http:// applicant to determine whether granting
To view comments, as well as any www.regulations.gov, including any the exemption will achieve the required
documents mentioned in this preamble, personal information provided. Please level of safety mandated by statute.
go to http://www.regulations.gov and in see the Privacy Act heading below for The physical qualification standard
the search box insert the docket number further information. for drivers regarding diabetes found in
VerDate Sep<11>2014 22:48 Jan 12, 2018 Jkt 244001 PO 00000 Frm 00170 Fmt 4703 Sfmt 4703 E:\FR\FM\16JAN1.SGM 16JAN1](https://thefederalregister.org/doc/83_FR_2310/page/1.svg)
![2306 Federal Register / Vol. 83, No. 10 / Tuesday, January 16, 2018 / Notices
address, an email address, or a phone DEPARTMENT OF TRANSPORTATION FMCSA–2015–0070; FMCSA–2015–
number in the body of your document 0071; FMCSA–2015–0072 using any of
so that FMCSA can contact you if there Federal Motor Carrier Safety the following methods:
are questions regarding your Administration • Federal eRulemaking Portal: Go to
submission. http://www.regulations.gov. Follow the
[Docket No.; FMCSA–1999–5578; FMCSA–
1999–5748; FMCSA–2001–9258; FMCSA– online instructions for submitting
To submit your comment online, go to comments.
http://www.regulations.gov and in the 2001–10578; FMCSA–2002–11426; FMCSA–
2002–12844; FMCSA–2003–15892; FMCSA– • Mail: Docket Management Facility;
search box insert the docket number 2003–16241; FMCSA–2005–21711; FMCSA– U.S. Department of Transportation, 1200
FMCSA–2017–0287 and click the search 2005–22194; FMCSA–2007–27897; FMCSA– New Jersey Avenue SE, West Building
button. When the new screen appears, 2008–0231; FMCSA–2009–0054; FMCSA– Ground Floor, Room W12–140,
click on the blue ‘‘Comment Now!’’ 2009–0154; FMCSA–2009–0206; FMCSA– Washington, DC 20590–0001.
button on the right hand side of the 2011–0092; FMCSA–2011–0124; FMCSA– • Hand Delivery: West Building
page. On the new page, enter 2011–0142; FMCSA–2011–0276; FMCSA– Ground Floor, Room W12–140, 1200
2011–26690; FMCSA–2013–0025; FMCSA– New Jersey Avenue SE, Washington,
information required including the 2013–0027; FMCSA–2013–0028; FMCSA–
specific section of this document to DC, between 9 a.m. and 5 p.m., ET,
2013–0029; FMCSA–2013–0030; FMCSA–
which each comment applies, and 2013–0165; FMCSA–2013–0166; FMCSA–
Monday through Friday, except Federal
provide a reason for each suggestion or 2013–0168; FMCSA–2013–0169; FMCSA– Holidays.
recommendation. If you submit your 2014–0303; FMCSA–2015–0055; FMCSA– • Fax: 1–202–493–2251.
2015–0056; FMCSA–2015–0070; FMCSA– Instructions: Each submission must
comments by mail or hand delivery,
2015–0071; FMCSA–2015–0072] include the Agency name and the
submit them in an unbound format, no docket number(s) for this notice. Note
larger than 81⁄2 by 11 inches, suitable for Qualification of Drivers; Exemption that all comments received will be
copying and electronic filing. If you Applications; Vision posted without change to http://
submit comments by mail and would www.regulations.gov, including any
like to know that they reached the AGENCY: Federal Motor Carrier Safety personal information provided. Please
facility, please enclose a stamped, self- Administration (FMCSA), DOT. see the Privacy Act heading below for
addressed postcard or envelope. ACTION: Notice of renewal of further information.
exemptions; request for comments. Docket: For access to the docket to
We will consider all comments and
materials received during the comment read background documents or
SUMMARY: FMCSA announces its
period. FMCSA may issue a final comments, go to http://
decision to renew exemptions for 109
www.regulations.gov at any time or
determination at any time after the close individuals from the vision requirement
Room W12–140 on the ground level of
of the comment period. in the Federal Motor Carrier Safety
the West Building, 1200 New Jersey
Regulations (FMCSRs) for interstate
V. Viewing Comments and Documents Avenue SE, Washington, DC, between 9
commercial motor vehicle (CMV)
a.m. and 5 p.m., ET, Monday through
To view comments, as well as any drivers. The exemptions enable these
Friday, except Federal holidays. The
documents mentioned in this preamble, individuals to continue to operate CMVs
FDMS is available 24 hours each day,
go to http://www.regulations.gov and in in interstate commerce without meeting
ET, 365 days each year. If you want
the search box insert the docket number the vision requirements in one eye. acknowledgment that we received your
FMCSA–2017–0287 and click ‘‘Search.’’ DATES: Each group of renewed comments, please include a self-
Next, click ‘‘Open Docket Folder’’ and exemptions were applicable on the addressed, stamped envelope or
you will find all documents and dates stated in the discussions below postcard or print the acknowledgement
and will expire on the dates stated in page that appears after submitting
comments related to this notice.
the discussions below. Comments must comments online.
Issued on: January 5, 2018. be received on or before February 15, Privacy Act: In accordance with 5
Larry W. Minor, 2018. U.S.C. 553(c), DOT solicits comments
Associate Administrator for Policy. ADDRESSES: You may submit comments from the public to better inform its
[FR Doc. 2018–00562 Filed 1–12–18; 8:45 am] bearing the Federal Docket Management rulemaking process. DOT posts these
BILLING CODE 4910–EX–P System (FDMS) Docket No.; FMCSA– comments, without edit, including any
1999–5578; FMCSA–1999–5748; personal information the commenter
FMCSA–2001–9258; FMCSA–2001– provides, to http://www.regulations.gov,
10578; FMCSA–2002–11426; FMCSA– as described in the system of records
2002–12844; FMCSA–2003–15892; notice (DOT/ALL–14 FDMS), which can
FMCSA–2003–16241; FMCSA–2005– be reviewed at http://www.dot.gov/
21711; FMCSA–2005–22194; FMCSA– privacy.
2007–27897; FMCSA–2008–0231; FOR FURTHER INFORMATION CONTACT: Ms.
FMCSA–2009–0054; FMCSA–2009– Christine A. Hydock, Chief, Medical
0154; FMCSA–2009–0206; FMCSA– Programs Division, 202–366–4001,
2011–0092; FMCSA–2011–0124; fmcsamedical@dot.gov, FMCSA,
FMCSA–2011–0142; FMCSA–2011– Department of Transportation, 1200
0276; FMCSA–2011–26690; FMCSA– New Jersey Avenue SE, Room W64–224,
daltland on DSKBBV9HB2PROD with NOTICES
2013–0025; FMCSA–2013–0027; Washington, DC 20590–0001. Office
FMCSA–2013–0028; FMCSA–2013– hours are from 8:30 a.m. to 5 p.m., ET,
0029; FMCSA–2013–0030; FMCSA– Monday through Friday, except Federal
2013–0165; FMCSA–2013–0166; holidays. If you have questions
FMCSA–2013–0168; FMCSA–2013– regarding viewing or submitting
0169; FMCSA–2014–0303; FMCSA– material to the docket, contact Docket
2015–0055; FMCSA–2015–0056; Services, telephone (202) 366–9826.
VerDate Sep<11>2014 22:48 Jan 12, 2018 Jkt 244001 PO 00000 Frm 00176 Fmt 4703 Sfmt 4703 E:\FR\FM\16JAN1.SGM 16JAN1](https://thefederalregister.org/doc/83_FR_2310/page/7.svg)
Document Created: 2018-01-13 02:02:47
Document Modified: 2018-01-13 02:02:47
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice of applications for exemption; request for comments. | |
| Dates | Comments must be received on or before February 15, 2018. | |
| Contact | Ms. Christine A. Hydock, Chief, Medical Programs Division, (202) 366-4001, [email protected], FMCSA, Department of Transportation, 1200 New Jersey Avenue SE, Room W64-224, Washington, DC 20590-0001. Office hours are 8:30 a.m. to 5 p.m., e.t., Monday through Friday, except Federal holidays. If you have questions regarding viewing or submitting material to the docket, contact Docket Services, telephone (202) 366-9826. | |
| FR Citation | 83 FR 2300 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR